Microbial sciences company Seed Health closed a $40 million Series A financing round and Dutch company Anavo Therapeutics announced seed financing totaling €20 million ($24 million) to discover small molecules that target phosphatases.

On the back of a $135 million public offering in February, rare disease gene therapy company Krystal Biotech Inc. launched subsidiary Jeune Inc. to promote gene therapies for aesthetic skin conditions.

In a historical move, healthcare investor giant Deerfield Management entered a second partnership with one of its academic collaborators, investing up to $130 million over the next ten years into Dana-Farber Cancer Institute to advance the development of new therapeutics and diagnostic tools for cancer patients.

Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.

RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.

BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.

rBIO launched with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.

Remix Therapeutics officially launched with $81 million in financing, with the funds to be used to support the development of the company’s REMaster technology platform while advancing a pipeline of RNA processing targeted therapeutics.

With $29 million in the company’s pocket, biotech Libra Therapeutics launched to take on neurodegenerative disease, with three pre-clinical programs ready to roll.

ATAI Life Sciences launched EmpathBio, a wholly owned subsidiary focused on developing derivatives of 3,4-methylenedioxy-methamphetamine for the treatment of post-traumatic stress disorder (PTSD).